GVAX: Phase III started

CEGE began the U.S. Phase III VITAL-1 trial comparing GVAX to docetaxel in about 600 patients. The trial has an SPA from FDA (see BioCentury, May 17). CEGE expects to begin a second Phase III trial, V...